SPA
COGT icon

Sherbrooke Park Advisers’s Cogent Biosciences COGT Stock Holding History

Sherbrooke Park Advisers’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,038
Closed -$93.6K – 545
2025
Q2 		$93.6K Buy
+13,038
New +$72.3K 0.04% 469

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Sherbrooke Park Advisers's COGT Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Cogent Biosciences (COGT) in Q3 2025, closing a stake of 13,038 shares — an estimated $93.6K sold.

Sherbrooke Park Advisers first reported a position in COGT in Q2 2025 and held it in 1 quarter. The position peaked at $93.6K in Q2 2025. 195 funds tracked by Wall St. Rank hold COGT as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Cogent Biosciences position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,038 Cogent Biosciences shares in Q3 2025, an estimated $93.6K.
  • Sherbrooke Park Advisers first reported a position in Cogent Biosciences in Q2 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Cogent Biosciences position peaked at $93.6K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.